Home/Biosimilar Atlas/Companies/Mochida Pharmaceutical

Mochida Pharmaceutical

Biosimilar developer, Japan. 5 development products across 5 molecules: adalimumab, etanercept, pegfilgrastim, teriparatide, tocilizumab.

First approval in the Atlas: Jan 2018, Etanercept BS MA, etanercept (PMDA)
FDAproducts approved0
EMAproducts approved0
MHRAproducts approved0
PMDAproducts approved5
HCproducts approved0
CDSCOproducts approved0
EDEproducts registered0
Connections
5molecules5products1 of 7markets0candidates in trials8companies on the same molecules

About Mochida Pharmaceutical

Mochida is a Japanese company with five biosimilar approvals, all in Japan: etanercept in 2018, the first there, developed by LG Chem; teriparatide in 2019, the only one in Japan; adalimumab in 2021; pegfilgrastim in 2023, the only one in Japan; and tocilizumab in 2026. Apart from the etanercept, Mochida does not name the developers of its products.

Portfolio by market

MoleculeProductFDAEMAMHRAPMDAHCCDSCOEDEMarkets
AdalimumabAdalimumab BS MA···Mar 2021···1/7
EtanerceptEtanercept BS MA LBEC0101···Jan 2018···1/7
PegfilgrastimPegfilgrastim BS Mochida / Nipro···Sep 2023···1/7
TeriparatideTeriparatide BS Mochida···Sep 2019···1/7
TocilizumabTocilizumab BS MA···Mar 2026···1/7

Month shown is the first approval or registration of that product in that market.

Also holds or markets

Products developed by another company for which Mochida Pharmaceutical is the licence holder or applicant in one or more markets.

MoleculeBrandMarketHolder or applicantApprovedDeveloper
FilgrastimFilgrastim BS F / MochidaPMDAFuji Pharma; Mochida PharmaceuticalNov 2012Fuji Pharma (with Mochida)

Companies on the same molecules

Developers whose portfolios overlap most with Mochida Pharmaceutical, by number of shared molecules. Overlap is the clearest sign of who competes with whom for the same tenders and licensing partners.

Fresenius KabiThree shared molecules: adalimumab, pegfilgrastim, tocilizumab5 molecules in its portfolioIntas PharmaceuticalsThree shared molecules: etanercept, pegfilgrastim, teriparatide12 molecules in its portfolioSandozThree shared molecules: adalimumab, etanercept, pegfilgrastim10 molecules in its portfolioCelltrionTwo shared molecules: adalimumab, tocilizumab10 molecules in its portfolioCoherus BioSciencesTwo shared molecules: adalimumab, pegfilgrastim2 molecules in its portfolioDr. Reddy's LaboratoriesTwo shared molecules: pegfilgrastim, teriparatide6 molecules in its portfolioEnzene BiosciencesTwo shared molecules: adalimumab, teriparatide6 molecules in its portfolioGedeon RichterTwo shared molecules: teriparatide, tocilizumab4 molecules in its portfolio

Chronology

Compare Mochida Pharmaceutical with other developers on the comparison page.

Considering a partner, a licence or a new market for a biosimilar portfolio? EvySaif's regulatory strategy and value dossier work covers the regulatory and market-access side of that decision.

Planning your biosimilar strategy?

EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.

Talk to a biosimilar regulatory consultant
Data current to September 2026.